SEC Tracker
Get the app

Provectus Biopharmaceuticals PVCT

Provectus Biopharmaceuticals Q2 FY26: net loss $983K; diluted EPS $0.00

Provectus Biopharmaceuticals (PVCT) filed a 10-Q with the SEC on Aug 13, 2026, 1:22 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Provectus Biopharmaceuticals reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$983KAgainst −$1.8M in Q2 FY2510-Q income statement, on EDGAR
  2. Diluted EPS$0.00Against $0.00 in Q2 FY2510-Q income statement, on EDGAR
  3. Cash and cash equivalents$1.2M+200% from $386K in Q2 FY2510-Q balance sheet, on EDGAR
  4. Cash from operations−$358KAgainst −$523K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Get the app

Get an email when Provectus Biopharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.